Rheumatology Pay Up (9.25.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
Read Article
Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 cont either CZP or ADA throughout PREG. Rates of miscarriage, LBW, congenital anomalies, comparable w/ https://t.co/H5GLrvxwPv
Dr. John Cush @RheumNow( View Tweet )
It’s almost time. 🔥
Registration for RheumNow Live 2027 opens OCTOBER 1.
Two days of practical, engaging rheumatology education designed to challenge how you think and influence how you practice.
📅 Jan 30–31, 2027
📍 Dallas + Online https://t.co/Ju0zzYX8Tl
Dr. John Cush @RheumNow( View Tweet )
Obesity in Rheumatic Diseases: More than just a Comorbidity
https://t.co/0QJ188HYSm https://t.co/3L09m2cowl
Dr. John Cush @RheumNow( View Tweet )
Obesity and Psoriatic Disease
Mason Arbabi, MD and Juliana S. Simonetti, MD
Obesity is a clinically important comorbidity in psoriasis and psoriatic arthritis. Excess adiposity contributes to systemic inflammation and cardiometabolic risk and may adversely affect disease severity and response to some systemic therapies. Intentional weight loss should be considered an
Read Article
Phenotypic cluster analysis of 134 CPPD pts from COLCHICORT & CHRONIC-CPPD European cohorts ID 4 Grps: 1) C1 monoarticular recurrent flares, older, W, ^CRP; 2) C2 monoarticular w persistent arthritis; 3) C3 polyarthritis lower CRP; 4) C4 polyarticular (spine/shoulder( & recurrent https://t.co/ghMCmDLCki
Dr. John Cush @RheumNow( View Tweet )
Lifestyle and Incretin Therapy Advice for Rheumatologists
As GLP-1/GIP receptor agonists become standard co-management tools for obese patients with RA, PsA, axSpA, and gout, this JAMA Insights perspective by Kushner, et al. reframes lifestyle counseling as an adjunct to pharmacotherapy - a reversal of the traditional model. This has with direct
Read Article
Discussing Weight Loss: 3 Minute Script
Dr. Jack Cush's 3 Minute Script as discussed in his Introducing Weight Loss video.
https://t.co/JRWAPc5if5 https://t.co/jI65VzTIfs
Dr. John Cush @RheumNow( View Tweet )
Obesity and Rheumatic Disease
Presented as part of RheumNow's "The Obesity Imperative" campaign.
https://t.co/d2fl4EJX8Q https://t.co/AZGfKRvZrx
Dr. John Cush @RheumNow( View Tweet )
Early RA Referral Clinics Work (9.18.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
Read Article
Obesity Journal Club: Tuesday Nite Rheumatology
The Obesity Journal Club explores the TOGETHER PsA and STEP 9 trials and what emerging evidence tells us about the relationship between obesity, weight loss, and rheumatic disease. Panelists discussed the results of these trials, https://t.co/3C1RLyRj0b
Dr. John Cush @RheumNow( View Tweet )
Weight Loss Improves Psoriatic Disease Substantially!
Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent https://t.co/BWeW7fzSC8
Dr. John Cush @RheumNow( View Tweet )
In 2022, Overweight & obesity affect 65.8% of Swiss PsA pts (vs gen pop.= 43%) and has increased since 2007. Obesity was assoc w/ elevated CRP (56% vs 37%), Inc Pt global assess (3.2 vs 2.8), & MD global (2.5 vs 2.1) & lower EQ-5D-3L(0.7 vs 0.8). https://t.co/xPoy4dgvlD https://t.co/aeB5N6LgCd
Dr. John Cush @RheumNow( View Tweet )
Obesity in Axial Spondyloarthritis: what are we missing beyond the scale?
Obesity in axSpA is not a minor comorbidity.
While obesity is more often discussed in psoriatic arthritis (PsA) due to the psoriasis-adipose tissue link which is mechanistically better studied and https://t.co/bFkoPmc0pC
Dr. John Cush @RheumNow( View Tweet )
FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw https://t.co/evzPtaTWI4
Dr. John Cush @RheumNow( View Tweet )
Together PsA 52 wk data (n 271): ACR50 plus >10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus >10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1 https://t.co/VdQJALdoJt
Dr. John Cush @RheumNow( View Tweet )
Weight Loss Improves Psoriatic Disease Substantially!
Even before the introduction of incretin therapy and bariatric surgery, many randomized and interventional studies (2019–2026) have consistently showed that weight loss produces clinically meaningful, dose-dependent improvement in both psoriasis and psoriatic arthritis.
Read Article
A Day of Infamy (9.11.2026)
Dr. Jack Cush reviews the news and journal reports from this past week on Rheumnow.com - including obesity, disappointing durability with GLP-1 drugs, AI diagnoses and worries about CV risk in ANCA-associated vasculitis. And take this week's RheumIQ quiz
Read Article
Meta-analysis 24 studies (3015 hidradenitis suppurativa pts) taking IL-17 inhibitor, IBD adverse events were rare, w/ no difference in IBD risk betw IL-17i & PBO (0.23% vs 0 of 2572 vs 1066 pts respectively) thru wk 16. The reported assocn of IL-17 inhibitors w/ IBD risk is https://t.co/kDwR5Fc1zI
Dr. John Cush @RheumNow( View Tweet )
Difficult PsA is called ‘difficult-to-manage’ (D2M) or ‘treatment-refractory’ dz (TRD). Data from 5 Nordic PsA registries 14,362 ps, D/Cs of ≥2/≥3/≥4 b/tsDMARDs in 36%/18%/10%. Freq of D2M low 2%/3%/3%, & TRD was 1.2%/1.2%/0.8%. Female #s, depression, & opioids incr w/ # of https://t.co/FkQU5BVRn2
Dr. John Cush @RheumNow( View Tweet )
High BMI decreases the odds for MDA in PsA, esp w/ TNFi Rx (but not Inflx, IL-17i, IL-12/23i, IL-23i, JAKi). Longitudinal PsA cohort 1291 pts (mean BMI 29); Higher BMI independently assoc w/ signif. lower odds for MDA (OR 0.97), also female, age, smoking, FM & Xray damage. https://t.co/zAJ8Pmk1HY
Dr. John Cush @RheumNow( View Tweet )
Join us for the first of four webinars this month!
This Journal Club will explore the TOGETHER PsA and STEP 9 trials, and what emerging evidence tells us about the complex relationship between obesity, weight loss and rheumatic disease.
The authors and leading experts will:
• https://t.co/xpnqim1VKH
Dr. John Cush @RheumNow( View Tweet )
Join us for the first of four webinars this month!
Our Journal Club explores the TOGETHER PsA and STEP 9 trials, and what emerging evidence reveals about obesity, weight loss and rheumatic disease.
Featuring Drs. Philip Mease, Tom Appleton and Jack Cush. https://t.co/KkVJPyhKF1
Dr. John Cush @RheumNow( View Tweet )
NEJM images: Jaccoud’s arthropathy is a chronic, deforming;from laxity of the ligaments & tendons (not damage to bone & cartilage). Deformities are reducible & no erosions on Xray. Jaccoud’s mimics RA, but most seen w/ SLE. https://t.co/99WDNcpT5c https://t.co/EdiGW1dDWY
Links:
Dr. John Cush @RheumNow( View Tweet )
NEW FROM EULAR: A real-world analysis of predictors of IBD in PsA.
🔎 In patients with PsA, signs and symptoms of IBD may appear before diagnosis, but do we know what to look for? Explore the poster: https://t.co/JX0Y0AQ07N
Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/zx9kjsiZfZ
Dr. John Cush @RheumNow( View Tweet )
Therapeutic Updates
Label update: Structural damage progression in active PsA
Sponsored by Johnson & Johnson Medical Affairs
Listen to Dr. Catherine Bakewell’s review of clinical data from a recent label update.
Read Post
PsA GRAPPA domains: Outcomes With a JAKi
Sponsored by AbbVie Medical Affairs + Health Impact
Dr. Schwartzman and Dr. Ruderman discuss how PsA disease activity across GRAPPA domains may guide treatment decisions, sharing both the evidence for and their experience with a JAKi across domains.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
Real-World Predictors and Early Indicators for IBD in Patients With PsA
Recent Blogs
A few years ago, when I would see a patient with rheumatic disease and increased BMI, I would often document it as obesity as a comorbidity, recommend weight loss and exercise, and then move on. My approach has changed.
Read Article
Dr. Cush provides a systematic approach to evaluating musculoskeletal and rheumatic complaints in clinical practice.
Read Article
Podcasts
PsA Topic Podcast compilation
EULAR 2026 Daily Podcast Day 4c-
EULAR 2026 Daily Podcast Day 4a
